Immunotherapy based on cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors have emerged as an effective treatment in melanoma, non-small cell lung carcinoma and glioma [3,4,5]. This evidence concerns the gene CTLA4 and melanoma.